NCT06058663 - Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 6, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2028

Conditions

Locally Advanced Intrahepatic CholangiocarcinomaOligometastatic Intrahepatic CholangiocarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma

Interventions

PROCEDURE

Angiography

Undergo mapping angiography

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

BIOLOGICAL

Durvalumab

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

BIOLOGICAL

Tremelimumab

Given IV

PROCEDURE

Yttrium-90 Microsphere Radioembolization

Receive transarterial Y90 radioembolization

Trial Locations (1)

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville